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ABSTRACT
Inhibition of bile acid transport by troglitazone (TGZ) and its major
metabolite, TGZ sulfate (TS), may lead to hepatocellular accumu-
lation of toxic bile acids; TS accumulation and hepatotoxicity may
be associated with impaired TS biliary excretion. This study
evaluated the impact of impaired transport of breast cancer
resistance protein (Bcrp) and multidrug resistance–associated
protein 2 (Mrp2) on the hepatobiliary disposition of generated
metabolites, TS and TGZ glucuronide (TG). Sandwich-cultured
hepatocytes (SCH) from Mrp2-deficient (TR–) rats in combination
with Bcrp knockdown using RNA interference were employed. The
biliary excretion index (BEI) of generated TS was not significantly
altered by impaired Bcrp (20.9 to 21.1%) and/or Mrp2 func-
tion (24.4% and 17.5% in WT and TR– rat SCH, respectively). Thus,
loss-of-function of Mrp2 and/or Bcrp do not appear to be risk factors
for increased hepatocellular TS accumulation in rats, potentially
because of a compensatory transporter(s) that excretes TS into
bile. Further investigations revealed that the compensatory
TS biliary transporter was not the bile salt export pump (Bsep) or
P-glycoprotein (P-gp). Interestingly, TGZ sulfation was signifi-
cantly decreased in TR– compared with WT rat SCH (total
recovery: 2.8 versus 5.0% of TGZ dose), resulting in decreased
hepatocellular TS accumulation, even though sulfotransferase
activity in TR– rat hepatocyte S9 fraction was similar. Hepatocel-
lular TG accumulation was significantly increased in TR– compared
with WT rat SCH due to increased glucuronidation and negligible
TG biliary excretion. These data emphasize that the interplay
between metabolite formation and excretion determines hepato-
cellular exposure to generated metabolites such as TS and TG.
Introduction
Drug-induced liver injury (DILI) is one of the primary reasons for
withdrawal of approved drugs from the market (Temple and Himmel,
2002); however, the ability to accurately predict a drug’s propensity
for DILI is limited due to a lack of understanding of the underlying
mechanism(s). One important proposed mechanism of DILI is inhibition
of bile salt export pump (BSEP)–mediated excretion of bile acids, which
may increase hepatic exposure to bile acids, ultimately leading to
necrotic and/or apoptotic cell death (Perez and Briz, 2009; Maillette de
Buy Wenniger and Beuers, 2010; Morgan et al., 2010; Dawson et al.,
2012). Many drugs that cause either cholestatic or mixed hepatocellular/
cholestatic liver injury [e.g., troglitazone (TGZ), bosentan, cyclosporine,
rifampin, sulindac, and glibenclamide] inhibit BSEP/Bsep-mediated
biliary excretion of bile acids (Bohme et al., 1994; Fattinger et al., 2001;
Funk et al., 2001a; Mano et al., 2007; Kis et al., 2009; Lee et al.,
2010b). However, only a small fraction of patients treated with BSEP
inhibitors develop DILI, suggesting that injury is driven by a combina-
tion of drug- and patient-specific risk factors. For drugs with a rare
incidence of DILI, hepatic exposure to the causative drugs/metabolites
may be high in the subset of patients who develop DILI. It is also
possible that toxic reactions triggered by drug exposure may develop
into severe liver injury in a subset of susceptible patients. Potential
patient-specific risk factors that may influence drug disposition and/or
toxicity include age, gender, activation of the innate immune system,
comedications, underlying disease, and/or genetic predisposition.
TGZ was the first marketed thiazolidinedione approved for the
treatment of type II noninsulin-dependent diabetes. However, 2% of
TGZ-treated patients developed serum alanine aminotransferase (ALT)
elevations more than 3-fold greater than the upper limit of normal
(Watkins and Whitcomb, 1998; St Peter et al., 2001). Subsequent to
reports of lethal DILI in humans, TGZ was withdrawn from worldwide
markets. Several mechanisms have been proposed to explain TGZ-
mediated DILI, including formation of reactive metabolites, mitochon-
drial toxicity, apoptosis, and inhibition of bile acid transport (Smith,
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2003; Chojkier, 2005). Clinical observations and in vivo studies in rats
have implicated a cholestatic mechanism in TGZ-induced hepatotoxicity
(Gitlin et al., 1998; Fukano et al., 2000; Funk et al., 2001a, b). In vitro
vesicular transport assays demonstrated that TGZ and its major
metabolite, TGZ sulfate (TS), are potent inhibitors of bile acid efflux
transporters, supporting the involvement of cholestasis in TGZ-induced
hepatotoxicity; TGZ inhibits human BSEP- and rat Bsep-mediated
bile acid transport with IC50 values of 2.7–5.9 and 3.9–10.6 mM,
respectively (Funk et al., 2001a; Morgan et al., 2010; Dawson et al.,
2012). TS is a 10-fold more potent inhibitor of ATP-dependent transport
of taurocholate in rat liver canalicular membrane vesicles compared
with TGZ (Funk et al., 2001a). Data from our laboratory demonstrated
that TS also inhibits the hepatic basolateral efflux transport protein
multidrug resistance–associated protein 4 (MRP4) (Yang et al., 2011).
In humans and male rats, TGZ is metabolized extensively in the
liver, primarily by sulfation, with glucuronidation and oxidation as suc-
cessively less prominent metabolic pathways; TS exhibited 10-fold
higher plasma concentrations than TGZ, and was excreted primarily into
bile, suggesting that TGZ metabolism and excretion were similar in
humans and male rats (Kawai et al., 1997; Loi et al., 1997; Loi et al.,
1999). Previously published data suggested that TS is excreted into bile
predominantly via breast cancer resistance protein (Bcrp) and multidrug
resistance-associated protein 2 (Mrp2) (Kostrubsky et al., 2001;
Enokizono et al., 2007). Extensive hepatic accumulation of TS (Kawai
et al., 1997; Lee et al., 2010a), coupled with the finding that TS potently
inhibits bile acid transporters (e.g., BSEP, MRP4), led to the hypothesis
that TS is primarily responsible for altered bile acid disposition and
subsequent hepatotoxicity; impaired function of Bcrp and Mrp2 (e.g.,
attributable to underlying disease, genetic variations, or drug-drug in-
teractions) would increase hepatocellular TS accumulation and enhance
inhibition of bile acid transport (Fig. 1).
In this study, the hepatobiliary disposition of TGZ and generated
metabolites, TS and TG, was examined in rat sandwich-cultured
hepatocytes (SCH) in the setting of impaired Bcrp and Mrp2 function.
A novel experimental system was employed to quantitatively assess
the effects of impaired function of Bcrp (using RNA interference
technique) in combination with Mrp2-deficient TR– rats (Yang et al.,
2014). Differential metabolism of TGZ also was investigated using
S9 fractions prepared from liver tissues of WT and TR– rats. This
work highlights the importance of considering both metabolic and
transport pathways when predicting hepatocellular exposure to
generated metabolites.
Materials and Methods
TGZ was purchased from Cayman Chemical Company (Ann Arbor, MI).
TS, TGZ glucuronide (TG), and TGZ quinone (TQ) were kindly provided by
Daiichi-Sankyo Co., Ltd. (Tokyo, Japan). TS also was synthesized from TGZ
in-house (Saha et al., 2010). [3H]Taurocholate (5 Ci/mmol; purity .97%) was
purchased from PerkinElmer (Waltham, MA). [3H]Rosuvastatin (10 Ci/mmol;
purity.99%) was purchased from American Radiolabeled Chemicals, Inc. (St.
Louis, MO). Non-radiolabeled rosuvastatin was purchased from Toronto
Research Chemicals Inc. (Toronto, Ontario, Canada). Taurocholate, Triton
X-100, Hanks’ balanced salt solution (HBSS) premix, HBSS modified (with
no calcium chloride, magnesium sulfate, phenol red, and sodium bicarbonate)
premix, dexamethasone, penicillin-streptomycin solution, and collagenase (type
IV) were purchased from Sigma-Aldrich (St. Louis, MO). Dimethyl sulfoxide
(DMSO) was obtained from Thermo Fisher Scientific (Waltham, MA). Gibco
brand fetal bovine serum, recombinant human insulin, and Dulbecco’s
modified Eagle’s medium (DMEM), and membrane vesicles prepared from
rat Bsep-overexpressing Sf9 cells (Sf9-Bsep) and control Sf9 cells (Sf9-control)
were purchased from Life Technologies (Carlsbad, CA). Insulin/transferrin/
selenium (ITS) culture supplement, BioCoat culture plates, and Matrigel
extracellular matrix were purchased from BD Biosciences Discovery Labware
(Bedford, MA). GF120918 (elacridar) was a generous gift from GlaxoSmith-
Kline (Research Triangle Park, NC). All other chemicals and reagents were of
analytical grade and were readily available from commercial sources.
Hepatocyte Isolation and Culture in a Sandwich Configuration.
Hepatocytes were isolated from male Wistar rats (270–300 g; Charles River
Laboratories, Inc., Wilmington, MA) and TR– rats (220–300 g, bred in-house;
breeding stock obtained from Dr. Mary Vore, University of Kentucky,
Lexington, KY) using a two-step collagenase perfusion method previously
described (LeCluyse et al., 1996). Animals had free access to water and food
before surgery and were allowed to acclimate for at least 5 days. All animal
procedures complied with the guidelines of the Institutional Animal Care and
Use Committee (University of North Carolina, Chapel Hill, NC). Hepatocytes
were seeded onto 24-well BioCoat culture plates at a density of 0.35  106
cells/well in seeding medium (DMEM containing 5% fetal bovine serum,
10 mM insulin, 1 mM dexamethasone, 2 mM L-glutamine, 1% MEM
nonessential amino acids, 100 IU penicillin G sodium, and 100 mg of
streptomycin) as described previously (Swift et al., 2010). Hepatocytes were
incubated for 1 hour at 37°C in a humidified incubator (95% O2, 5% CO2) and
allowed to attach to the collagen substratum, after which time the medium was
aspirated to remove unattached cells, and replaced with fresh medium. On the
next day, cells were overlaid with BD Matrigel at a concentration of 0.25 mg/ml
in ice-cold feeding medium (DMEM supplemented with 0.1 mM dexametha-
sone, 2 mM L-glutamine, 1% MEM nonessential amino acids, 100 IU penicillin
G sodium, 100 mg of streptomycin, and 1% insulin/transferrin/selenium culture
supplement. The culture medium was changed daily until experiments were
performed on day 4.
Knockdown of Bcrp Protein in WT and TR– Rat SCH. Adenoviral
vectors expressing short hairpin RNA targeting Bcrp (Ad-siBcrp) or a nontarget
control (Ad-siNT) were prepared as described previously (Yue et al., 2009).
One hour after seeding on day 0, hepatocytes were infected with Ad-siBcrp or
Ad-siNT at multiplicity of infection of 5 by replacing the seeding medium with
fresh seeding medium containing virus. On the next day, medium including
viruses were removed, and cells were overlaid with Matrigel as described earlier.
Accumulation of TGZ and Generated Metabolites in WT and TR– Rat
SCH in the Absence or Presence of Bcrp Knockdown. Following 30-minute
exposure to 0.5 ml of feeding medium containing 10 mM TGZ, 0.2-ml aliquots
of medium were collected from day 4 WT and TR– rat SCH in the absence or
presence of Bcrp knockdown. The remaining culture medium was completely
aspirated, and SCH were rinsed with 0.5 ml/well of warm standard (Ca2+
-containing) or Ca2+-free HBSS buffers. After rinses, HBSS buffers were
aspirated, and SCH were incubated with 0.5 ml of HBSS buffers (standard or
Ca2+-free) at 37°C for 5 minutes. After incubation, the HBSS buffers were
aspirated from all wells. Plates were sealed and stored at –80°C until analysis.
Membrane Vesicle Assay. Membrane vesicles (Sf9-control and Sf9-Bsep,
10 and 25 mg/reaction for taurocholate and TS uptake, respectively) were
incubated at 37°C with the substrate (5 mM taurocholate or 100 mM TS) in Tris-
sucrose buffer (TSB) containing MgCl2 (10 mM), creatine phosphate (10 mM),
creatine kinase (100 mg/ml), adenosine triphosphate (ATP) or adenosine
Fig. 1. Proposed mechanism of troglitazone (TGZ)-mediated hepatotoxicity. (1)
Impaired BCRP and/or MRP2 function (2) causes accumulation of TGZ sulfate (TS)
(the major TGZ metabolite and a potent inhibitor of bile acid transport proteins) in
hepatocytes, (3) which inhibits bile acid excretion leading to bile acid accumulation
and (4) hepatotoxicity.
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monophosphate (AMP) (4 mM) in a final volume of 50 ml. The assays were
performed in three separate experiments in triplicate. After incubation for
5 minutes, the reaction was stopped by addition of 800 ml of ice-cold TSB and
immediately filtered using Type A/E glass fiber filter (Pall Corporation, Port
Washington, NY) presoaked in TSB overnight. Under aspiration, the filters
were washed twice with ice-cold TSB using a vacuum filtration system. Glass
filters were transferred to glass vials, and 1 ml of Bio-Safe II (Research
Products International, Mount Prospect, IL) was added before counting
radioactivity of taurocholate using the Tri-Carb 3100TR liquid scintillation
analyzer (PerkinElmer, Waltham, MA). For liquid chromatography coupled
with tandem mass spectrometry (LC-MS/MS) analysis of TS, glass filters were
dissolved with 1 ml of methanol including 1 nM ethyl warfarin (internal
standard). Following vortex mixing and sonication, the supernatant was
transferred to microcentrifuge tubes and centrifuged for 20 minutes at 4°C. After
centrifugation, 500 ml of supernatant was transferred to a 96-well LC-MS/MS plate,
evaporated using SPE Dry 96 (Biotage, Uppsala, Sweden), and reconstituted with
100 ml 1:1 mixture of methanol and DMSO. The ATP-dependent uptake of
substrate was calculated by subtracting substrate uptake in the presence of
AMP from substrate uptake in the presence of ATP.
Effects of GF120918 on the Biliary Excretion of TS in WT and TR– Rat
SCH. WT and TR– rat SCH were preincubated with 0.5 mM GF120918 or
vehicle control for 10 minutes followed by 30-minute exposure to 0.5 ml of
feeding medium containing 10 mM TGZ and 0.5 mM GF120918 (or vehicle
control). After incubation, the culture medium was completely aspirated, and
SCH were rinsed with 0.5 ml/well of warm standard or Ca2+-free HBSS
buffers. After the second rinse, HBSS buffers were aspirated, and SCH were
incubated with 0.5 ml of HBSS buffers (standard or Ca2+-free) at 37°C for
5 minutes. After incubation, the HBSS buffers were aspirated from all wells.
Plates were sealed and stored at –80°C until analysis.
In Vitro Metabolism of TGZ in S9 Fraction. S9 fractions were prepared
from liver tissues of WT and TR– rats (n = 3, respectively) according to standard
procedures and stored at –80°C until used (Hill, 2004). Protein concentration
was determined by the BCA protein assay (Pierce Biotechnology/Thermo
Scientific, Rockford, IL) using human serum albumin (standard solution;
Sigma-Aldrich) as a standard. Reaction mixture [95 ml of Tris-HCl buffer (pH
7.5, 0.1 M) containing 39-phosphoadenosine-59-phosphosulfate (PAPS; final
concentration 0.1 mM), uridine 59-diphosphoglucuronic acid (UDPGA; final
concentration 2 mM), nicotinamide adenine dinucleotide phosphate (reduced,
NADPH; final concentration 1 mM), alamethicin (final concentration 25 ml/
ml), and TGZ (final concentrations of 1 or 10 mM)] was preincubated for
5 minutes at 37°C. TGZ was dissolved in DMSO; the final concentration of
DMSO in the reaction mixture was 0.2%. TGZ concentrations of 1 and 10 mM
were selected for investigation because they yielded unbound concentrations of
TGZ in the S9 fraction that were similar to the unbound concentrations in
hepatocytes. Intracellular total concentrations of TGZ ranged from 100 to 250
mM after a 30-minute incubation of WT and TR– rat SCH with 10 mM TGZ
(Lee et al., 2010a). Assuming that the intracellular unbound fraction (fu) is
equal to the plasma fu of 0.000921 (Izumi et al., 1996), intracellular
concentrations of unbound TGZ would be in the range of 0.09–0.23 mM.
TGZ also is highly bound to microsomal and cytosolic protein (TGZ fu was
0.01 and 0.03 in 2 mg/ml of rat liver microsomes and 0.5 mg/ml of rat liver
cytosol, respectively) (Izumi et al., 1997); therefore, 1 and 10 mM total TGZ in
S9 fraction would result in TGZ unbound concentrations of 0.018 - 0.18 uM,
which are similar to expected intracellular unbound TGZ concentrations in rat
SCH. The reaction was started by adding 5 ml of the S9 fraction (final
concentration 1 mg/ml). The reaction was stopped after 3 minutes by mixing with
200 ml of ice-cold acetonitrile containing 15 nM ethyl warfarin (analytical
internal standard). The 3-minute time point was chosen on the basis of the
reported linear range to calculate the initial velocity of TS and TG formation
(Izumi et al., 1997). The reaction mixture was centrifuged for 20 minutes at 4°C,
and the supernatant was transferred to 96-well LC-MS/MS plates for analysis. To
determine desulfation of TS, 5 ml of TS (final concentration of 100 mM) was
incubated with 95 ml of 0.1M Tris-HCl buffer (pH 7.5) containing S9 fraction
(final concentration 1 mg/ml) for 30 minutes, and the same procedure was
followed as detailed above.
LC-MS/MS Analysis. TGZ and generated metabolites were analyzed by
LC-MS/MS as described previously (Lee et al., 2010a). Briefly, the medium and
cells or cells+bile lysate samples were centrifuged at 12,000g for 10 minutes
at 4°C, and the supernatant was diluted 1:6 (v/v) with 79%:21% (v/v) methanol/
water containing the internal standard (ethyl warfarin). An Applied Biosystems
API 4000 triple quadrupole mass spectrometer with a TurbolonSpray Ion
Source (Applied Biosystems, Foster City, CA) was used for analysis in
negative ionization mode. The ranges of the standard curves were extended by
adding additional points to the previously reported range (Lee et al., 2010a);
eleven-point (5–10000 nM; TGZ) or ten-point (5–5000 nM; TS, TG, and TQ)
calibration curves were constructed as composites of TGZ (440.0→397.1),
TS (520.2→440.1), TG (616.2→440.1), and TQ (456.1→413.1) by using peak
area ratios of analyte and ethyl warfarin (320.8→160.9). All points on the
curves back-calculated to within 15% of the nominal value. Care was taken to
minimize the light-sensitive degradation of TGZ during all experimental
procedures.
Data Analysis and Statistics. TGZ accumulation was corrected for
nonspecific binding to the BioCoat plate without cells, and normalized to
protein concentration measured by the BCA protein assay (Pierce Biotechnol-
ogy). To account for the incompatibility of the protein assay with methanol, the
average protein concentration for standard HBSS or Ca2+-free HBSS incubations
in a representative plate from the same liver preparation was used to normalize
accumulation. The biliary excretion index (BEI; %), defined as the percentage of
accumulated substrate residing within the bile canaliculi, was calculated using B-
CLEAR® technology (Qualyst Transporter Solutions, Durham, NC) according to
the following equation (Liu et al., 1999):




Effects of viral infection (noninfected versus Ad-siNT versus Ad-siBcrp)
and rat type (WT versus TR–) on hepatobiliary disposition (accumulation in
cells+bile, cellular accumulation, and BEI) and recovery of TGZ and its
metabolites were evaluated using a two-way analysis of variance (ANOVA)
followed by Tukey’s post-hoc test. Two-way ANOVA also was used to
evaluate the effects of GF120918 and rat type (WT versus TR–) on
hepatobiliary disposition of TS and TG. Student’s t test was used to compare
ATP-dependent substrate transport in Sf9-Bsep versus Sf9-control, and the
initial velocity of TS/TG formation in S9 fractions prepared from livers of
WT and TR– rats. In all cases, P , 0.05 was considered statistically signi-
ficant. All analyses were performed using SigmaStat 3.5 (Systat Software
Inc., San Jose, CA).
Results
Hepatobiliary Disposition of TGZ and Generated Metabolites in
WT and TR– Rat SCH in the Absence or Presence of Bcrp. Loss of
function of Mrp2 and Bcrp was validated in this experiment using
rosuvastatin, a dual substrate of Mrp2 and Bcrp; rosuvastatin BEI was
significantly decreased by impaired function of Mrp2 or Bcrp, and
biliary excretion was almost ablated in Bcrp knockdown TR– rat SCH
(Yang et al., 2014). Accumulation of TGZ and generated metabolites
in cells+bile, cells, and medium after a 30-minute incubation of WT
and TR– rat SCH with 10 mM TGZ is shown in Figs. 2 and 3. BEI
values of TS and TG in noninfected WT hepatocytes were 24 and
49%, respectively (Fig. 2, B and C); biliary excretion of TGZ
(Fig. 2A) and TQ (data not shown) was negligible, consistent with
previously published data (Lee et al., 2010a). The hepatobiliary
disposition of TGZ and generated metabolites was not affected by
infection of the nontarget control adenoviral vector (Ad-siNT),
confirming that off-target effects of viral infection were negligible in
these studies. Unexpectedly, the BEI of TS was not altered by
impaired Mrp2 (TR–) and/or Bcrp function (Ad-siBcrp), suggesting
that other biliary transporters may compensate for the impaired
function of Mrp2 and Bcrp (Fig. 2B). Interestingly, TS accumulation
in cells+bile, cells, and medium was decreased in TR– rat SCH
compared with WT rat SCH (Figs. 2B and 3B). Bcrp knockdown did
not significantly alter TS accumulation in cells+bile, cells, or
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medium (Figs. 2B and 3B). The BEI of TG was significantly
decreased in TR– rat SCH compared with WT rat SCH but was not
influenced by knockdown of Bcrp (Fig. 2C). TG cellular
accumulation was significantly increased in TR– rat SCH compared
with WT rat SCH, whereas TG accumulation in cells+bile was not
altered (Fig. 2C). In TR– rat SCH, TG medium concentrations were
significantly higher compared with WT rat SCH (Fig. 3C). TG
accumulation in cells+bile, cells, and medium was not significantly
Fig. 2. Intracellular accumulation of troglitazone (TGZ) and generated metabolites [TGZ sulfate (TS) and TGZ glucuronide (TG)] in WT and TR– rat SCH in the absence or
presence of Bcrp knockdown. WT and TR– rat SCH were treated with 10 mM TGZ for 30 minutes in the absence [CTL (noninfected cells) and Ad-siNT (nontarget control)]
or presence (Ad-siBcrp) of Bcrp knockdown. Hepatobiliary disposition of (A) TGZ, (B) TS, and (C) TG were measured in cells+bile (solid bars) and in cells (open bars).
Effects of Bcrp knockdown (CTL versus Ad-siNT versus Ad-siBcrp) and rat type (WT versus TR–) on accumulation of TGZ and generated metabolites and biliary excretion
index (BEI; pink diamonds) of generated metabolites were evaluated using two-way ANOVA. Data represent mean 6 S.E.M. (n53 in triplicate); †P , 0.05, significantly
different from WT (cells+bile); ‡P , 0.05, significantly different from WT (cell); *P , 0.05, significantly different from WT (BEI).
Fig. 3. Accumulation of troglitazone (TGZ) and
generated metabolites [TGZ sulfate (TS) and TGZ
glucuronide (TG)] in the medium of WT and TR–
rat SCH in the absence or presence of Bcrp
knockdown. WT and TR– rat SCH were treated
with 10 mM TGZ for 30 minutes in the absence
[CTL (noninfected cells) and Ad-siNT (nontarget
control)] or presence (Ad-siBcrp) of Bcrp knock-
down. Concentrations of (A) TGZ, (B) TS, and
(C) TG were measured in medium. Effects
of Bcrp knockdown (CTL versus Ad-siNT versus
Ad-siBcrp) and Mrp2 deficiency (WT versus TR–)
on media concentrations of TGZ and generated
metabolites were evaluated using two-way
ANOVA. Data represent mean 6 S.E.M. (n53
in triplicate); *P , 0.05, significantly different
from WT.
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altered by Bcrp knockdown (Figs. 2C and 3C). TQ accumulation in
cells and cells+bile was significantly increased in TR– rat SCH in the
absence and presence of Bcrp knockdown compared with WT rat
SCH, but medium concentrations were not significantly different
(data not shown).
Differential Metabolism of TGZ in WT and TR– Rat SCH.
Cumulative recovery of TGZ and generated metabolites from medium,
hepatocytes, and bile was comparable among all groups (92.3–99.6%)
(Fig. 4A). After a 30-minute incubation, more than 80% of the TGZ
dose remained as parent compound in both WT and TR– SCH. Among
three generated metabolites, TS was predominant (4.8% of the dose
recovered in cells, bile, and medium), followed by TQ (1.5% of the
dose) and TG (0.9% of the dose) in noninfected WT rat SCH (Fig.
4A). In TR– rat SCH, total recovery (medium, hepatocytes, and bile)
of TS was significantly lower compared with WT rat SCH (Fig. 4A).
Total recovery of TG was significantly greater in TR– compared with
WT rat SCH (Fig. 4A). TS was recovered primarily from hepatocytes,
whereas TG was recovered primarily from the medium (Figs. 4, B and C).
Transport of TS in Membrane Vesicles from Bsep-Overexpressing
Sf9 Cells. To investigate the transport protein(s) involved in the
compensatory biliary excretion of TS in the absence of Mrp2 and Bcrp,
ATP-dependent uptake of 10 mM taurocholate (positive control) and
100 mM TS was determined in Sf9-control and Sf9-Bsep vesicles.
ATP-dependent taurocholate transport was 60-fold greater in Sf9-Bsep
vesicles compared with Sf9-control vesicles (Fig. 5). However,
ATP-dependent TS transport was comparable between Sf9-control and
Sf9-Bsep vesicles, indicating that TS is not transported by Bsep.
Effects of GF120918 on the Hepatobiliary Disposition of TGZ
and Generated Metabolites in WT and TR– Rat SCH. The BEI of
TS was not significantly altered by GF120918, a potent inhibitor
of Bcrp and P-glycoprotein (P-gp), nor by rat type (WT versus TR–)
(Fig. 6A). The accumulation of TS in cells+bile and cells was
significantly decreased in TR– rat SCH compared with WT rat SCH as
shown in Fig. 2B, but was not altered by the presence of GF120918.
The BEI of TG was significantly decreased in TR– rat SCH compared
with WT rat SCH, consistent with Fig. 2C, but was not altered by the
presence of GF120918 (Fig. 6B). TG accumulation in cells+bile and
cells was not influenced significantly by GF120918 or by rat type, but
there was a trend toward an increase in cellular TG accumulation in
TR– compared with WT rat SCH (Fig. 6B).
Fig. 4. Recovery of troglitazone (TGZ) and generated metabolites [TGZ sulfate (TS), TGZ glucuronide (TG), and TGZ quinone (TQ)] in WT and TR– rat SCH in the absence or
presence of Bcrp knockdown. WT and TR– rat SCH were treated with 10 mM TGZ for 30 minutes in the absence (CTL and Ad-siNT) or presence (Ad-siBcrp) of Bcrp
knockdown. (A) Total recovery of TGZ and generated metabolites in cells, bile, and medium are presented as % of the TGZ dose. Effects of Bcrp knockdown (CTL versus
AdsiNT versus Ad-siBcrp) and Mrp2 deficiency (WT versus TR–) on total recovery of TGZ and generated metabolites were evaluated using two-way ANOVA. *P , 0.05,
significantly different from WT. Recovery of TS (B) and TG (C) in cells, bile, and medium are presented as % of the TGZ dose.
Fig. 5. Bsep-mediated transport of taurocholate (TC) and troglitazone sulfate (TS)
in membrane vesicles. ATP-dependent transport of TC and TS in membrane vesicles
prepared from Sf9 cells overexpressing Bsep (Sf9-Bsep; open bars) or mock controls
(Sf9-control; solid bars). The data represent mean 6 S.E.M. (n = 3 in triplicate).
*P , 0.05, significantly different from mock controls.
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TGZMetabolism in S9 Fraction Prepared from Liver Tissues of
WT and TR– Rats. To investigate the differential metabolism
(i.e., sulfation and glucuronidation) of TGZ in WT and TR– rats,
formation of TS and TG was quantified after incubating 1 or 10 mM
TGZ with S9 fraction prepared from liver tissues of WT and TR– rats
for 3 minutes. These concentrations were selected for investigation
because they yielded unbound concentrations of TGZ in the S9 fraction
that were similar to the unbound concentrations in hepatocytes (see
Materials and Methods for details). The initial velocity of TS formation
in S9 fraction from WT and TR– rat liver tissue was comparable after
incubation with 1 and 10 mM TGZ, indicating that the activity of
sulfotransferases was not altered in TR– rats (Fig. 7). The initial
velocity of TG formation was increased by 15- and 6.5-fold in TR– rats
after incubation with 1 and 10 mM TGZ, respectively, consistent with
the increased recovery of TG in TR– rat SCH (Fig. 7). TS did not
undergo de-sulfation after incubation of 100 mM TS with S9 fractions
over a 30-minute period (data not shown).
Discussion
This study examined the effects of impaired function of Bcrp and/or
Mrp2 on the hepatobiliary disposition of TGZ and generated
metabolites, TS and TG; although TQ was measured, this investigation
did not focus on TQ because it is a minor metabolite that also is formed
by photo-oxidation (Fu et al., 1996). A recently established novel in
vitro system, rat SCH lacking Mrp2 (using Mrp2-deficient TR– rat) and
Bcrp (using adenoviral vectors expressing shRNA targeting Bcrp), was
employed (Yang et al., 2014). In addition, differential metabolism of
TGZ in WT and TR– rats was investigated by in vitro metabolism
studies using hepatic S9 fractions.
TGZ is metabolized by Phase I and II enzymes and the generated
metabolites are eliminated by multiple transport proteins. Conse-
quently, defects in relevant metabolic enzymes and/or transport
proteins attributable to genetic polymorphisms, underlying disease, or
coadministered drugs may predispose certain patients to TGZ-induced
hepatotoxicity. Hewitt et al. (2002) demonstrated that low CYP3A4
and UDP-glucuronosyltransferase (UGT) activity combined with high
sulfotransferase (SULT) activity was associated with TGZ toxicity in
human hepatocytes. Pharmacokinetic modeling and Monte Carlo
simulations in rat SCH revealed that intracellular concentrations of TS
may increase up to 5.7-fold when biliary excretion of TS is decreased
10-fold (Lee et al., 2010a), but effects of altered function of biliary
transporters on TS disposition have not been evaluated experimen-
tally. TS, a potent inhibitor of bile acid efflux transporters, is extensively
excreted into bile via Mrp2 and Bcrp (Kostrubsky et al., 2001;
Enokizono et al., 2007). Thus, we hypothesized that loss-of-function of
Bcrp and/or Mrp2 would result in decreased biliary excretion and
increased cellular accumulation of TS, which may lead to further
inhibition of bile acid transport and hepatotoxicity.
Unexpectedly, biliary excretion of TS was not altered by
loss-of-function of Bcrp and Mrp2, potentially attributable to the
presence of a compensatory canalicular protein that transports TS in
the absence of Mrp2 and Bcrp. It is not probable that residual Bcrp
expression played a role in TS transport, because loss-of-function of
Mrp2 and Bcrp in this experimental system was validated using
rosuvastatin, a dual substrate of Mrp2 and Bcrp. Biliary excretion of
rosuvastatin was almost ablated in Bcrp knockdown TR– rat SCH.
Thus, Bsep and P-gp were investigated as potential compensatory
transporters mediating the biliary excretion of TS. Although TS is
a potent Bsep inhibitor (Funk et al., 2001b), results from membrane
Fig. 6. Hepatobiliary disposition of troglitazone (TGZ) and generated metabolites [TGZ sulfate (TS) and TGZ glucuronide (TG)] in WT and TR– rat SCH in the absence or
presence of GF120918. WT and TR– rat SCH were incubated with 10 mM TGZ for 30 minutes in the absence or presence of GF120918. Hepatobiliary disposition of (A) TS
and (B) TG were measured in cells+bile (solid bars) and in cells (open bars). Effects of GF120198 and rat type (WT versus TR–) on accumulation and the biliary excretion
index (BEI; pink diamonds) of TS and TG were evaluated using two-way ANOVA. Data represent mean6 S.E.M. (n53 in triplicate). †P, 0.05, significantly different from
WT (cells+bile); ‡P , 0.05, significantly different from WT (cell); *P , 0.05, significantly different from WT (BEI).
Fig. 7. Metabolism of troglitazone (TGZ) in S9
fraction prepared from liver tissues of WT and TR–
rats. The initial velocity of TGZ sulfate (TS) and
TGZ glucuronide (TG) formation was obtained
after incubation of 1 and 10 mM TGZ with
S9 fractions prepared from liver tissues of WT
(solid bars) and TR– (open bars) rats. *P , 0.05,
significantly different from WT.
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vesicle studies demonstrated that TS is not transported by Bsep. P-gp is
probably not involved in TS biliary excretion because excretion of TS
into bile was not altered in the presence of GF120918, a potent
inhibitor of P-gp and Bcrp (Mao and Unadkat, 2005; Rautio et al.,
2006), in WT and TR– rat SCH. Other hepatic canalicular transporters,
such as multidrug and toxin extrusion protein 1 (Mate1) or multidrug
resistance P-glycoprotein 2 (Mdr2), might be involved in compensatory
TS biliary excretion. MATE1 typically transports hydrophilic organic
cations with low molecular weight (e.g., metformin, tetraethylammo-
nium, 1-methyl-4-phenylpyridinium, oxaliplatin), although transport of
anionic compounds (e.g., acyclovir, ganclyclovir, estrone sulfate) and
zwitterions (e.g., cephalexin, cephradine) has been reported (Klaassen
and Aleksunes, 2010; Hillgren et al., 2013). Mdr2 is the rodent
ortholog of human MDR3, a phosphatidylcholine flippase, which also
transports paclitaxel, digoxin, and verapamil (Smith et al., 2000).
Even though the BEI of TS remained the same, the total recovery of
TS was decreased in TR– compared with WT rat SCH on the basis
of decreased TS cellular accumulation and medium concentrations.
These data suggested that TGZ sulfation was decreased, or desulfation
of TS was increased in TR– rat SCH. TGZ is metabolized to TS
primarily by SULT1A1 and also by SULT1E1 in humans (Honma
et al., 2002). In rats, TS formation is four times faster in male rats
compared with female rats, which is consistent with greater expression
of Sult1a1 and Sult1e1 in male rats (Demyan et al., 1992; Liu and
Klaassen, 1996). Interestingly, protein levels of hepatic Sult1a1 and
Sult1e1 were comparable between WT and TR– rats (Johnson et al.,
2006; Sun et al., 2010), and our in vitro metabolism study using S9
fractions from livers of WT and TR– rats revealed that TS formation
rates were comparable. A decrease in net sulfation of estradiol-17
b-glucuronide (E217G) reported in TR
– rats was attributed to increased
desulfation of estradiol-3-sulfate-17b-glucuronide (Sun et al., 2010).
However, desulfation of TS to TGZ was not observed in S9 fraction
from livers of WT or TR– rats. It is possible that the availability
of 39-phosphoadenosine-59-phosphosulfate (PAPS) is less in TR–
compared with WT rat SCH. In rats and humans, sulfation can be
limited by the availability of the cofactor PAPS. PAPS is synthe-
sized rapidly by ATP-sulfurylase and adenosine-59-phosphosulfate
(APS)-kinase, but its availability is limited by hepatic sulfate
concentrations, which are largely dependent on circulating levels of
inorganic sulfate (Klaassen and Boles, 1997). TR– rat SCH may have
lower levels of PAPS precursors or lower activity of enzymes involved
in PAPS synthesis. These differences would not be detected in the
current experimental design, in which adequate PAPS was added
exogenously to the in vitro metabolism system. TR– rat SCH also may
have higher cellular concentrations of endogenous substrates (e.g., bile
acids) that deplete PAPS, leading to decreased recovery of TS.
Compared with WT rats, hepatic sulfation activities in TR– rats
have been reported to be modestly increased (i.e., acetaminophen,
4-methylumbelliferone), similar (i.e., harmol, E217G), or decreased
(i.e., resveratrol) in isolated perfused liver studies (Xiong et al.,
2000; Zamek-Gliszczynski et al., 2005; Zamek-Gliszczynski et al.,
2006; Maier-Salamon et al., 2008; Zamek-Gliszczynski et al., 2008;
Sun et al., 2010). However, with the exception of the harmol and
E217G studies, recovery was measured only in perfusate and bile,
and mass balance did not account for recovery in the liver tissue.
Further studies are warranted to investigate the mechanisms of
altered sulfation in TR– rats and the underlying reason for decreased
recovery of TS in TR– rat SCH.
As expected, TG biliary excretion was significantly decreased in
TR– rat SCH compared with WT rat SCH, but was not altered by Bcrp
knockdown, consistent with previous data that Mrp2 plays a major
role in the biliary excretion of TG (Kostrubsky et al., 2001). The
increase in total recovery of TG in cells, bile, and medium of TR– rat
SCH compared with WT rat SCH can be explained by increased
activity of UGT enzymes, as shown in the in vitro S9 metabolism
study. Species differences exist between humans and rats in UGT
isozymes responsible for TGZ glucuronidation. TG formation is
mediated primarily by UGT1A1 in humans, whereas Ugt2b2 is the
major isozyme responsible for TGZ glucuronidation in rats (Yoshigae
et al., 2000; Watanabe et al., 2002). Expression of hepatic Ugt1a
protein was increased in TR– rats (Johnson et al., 2006). Although
expression of hepatic Ugt2b2 in TR– rats has not been characterized,
the present in vitro S9 metabolism data suggest that expression and/or
activity of Ugt2b2 is increased in TR– rats. Overall, decreased biliary
excretion combined with increased glucuronidation led to significantly
increased cellular accumulation of TG in TR– compared with WT rat
SCH. Medium concentrations of TG also were increased in TR– rat
SCH, consistent with increased glucuronidation and increased
expression of the basolateral efflux transporter Mrp3 (Johnson et al.,
2006; Sun et al., 2010).
In conclusion, the present study revealed that loss-of-function of
Mrp2 and Bcrp is not a risk factor for increased hepatocellular TS
accumulation in rats. Whether these findings can be directly translated
to humans remains to be determined. Species differences in abundance,
substrate specificity, and/or affinity for canalicular transporters may
exist. For example, Mrp2 protein expression in rat liver tissue and fresh
hepatocytes was about 10-fold higher compared with humans (Li et al.,
2009). Mrp2 contributes to TS and TG biliary excretion in rats
(Kostrubsky et al., 2001), but the contribution of human MRP2 to TS
and TG biliary excretion has not been evaluated. To identify DILI risk
factors in humans, the results from the current study need to be
confirmed in primary human hepatocytes or human-derived cell
systems. In addition, this study demonstrated for the first time that in
TR– rat SCH, TGZ sulfation was decreased, but these changes were
not attributable to altered sulfotransferase activity. Evaluation of
hepatocellular exposure of a drug may be important in predicting
efficacy and/or toxicity if the liver is the site of action, or the parent
drug and/or generated metabolites elicit hepatotoxic effects. Alto-
gether, the results from the present study suggest that altered
hepatocellular exposure to hepatically-generated metabolites is de-
termined by both formation and excretion, and that compensatory
mechanisms may play important roles when elimination pathways are
impaired.
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